Transforming growth factor-β and natural killer T-cells are involved in the protective effect of a bacterial extract on type 1 diabetes

Diabetes

Volumn 55, Issue 1, 2006, Pages 179-185

  Alyanakian, Marie Alexandra ^a   Grela, Françoise ^a   Aumeunier, Aude ^a   Chiavaroli, Carlo ^b   Gouarin, Christine ^a   Bardel, Emilie ^a   Normier, Gerard ^b   Chatenoud, Lucienne ^a   Thieblemont, Nathalie ^a   Bach, Jean François ^a,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b OM PHARMA   (Switzerland)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LYSATE; CD1D ANTIGEN; CYTOKINE ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MONOCLONAL ANTIBODY; MYELOID DIFFERENTIATION FACTOR 88; OM 85; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM; CONTROLLED STUDY; DRUG EFFECT; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; MOUSE; MOUSE STRAIN; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

EID: 33644784891     PISSN: 00121797     EISSN: 00121797     Source Type: Journal    
DOI: 10.2337/diabetes.55.01.06.db05-0189     Document Type: Article

References (44)

1. Gale EA: The rise of childhood type 1 diabetes in the 20th century. Diabetes 51:3353-3361, 2002
2. Bach JF: The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 347:911-920, 2002
3. Feillet H, Bach JF: On the mechanisms of the protective effect of infections on type 1 diabetes. Clin Dev Immunol 11:191-194, 2004
4. Harada M, Kishimoto Y, Makino S: Prevention of overt diabetes and insulitis in NOD mice by a single BCG vaccination. Diabetes Res Clin Pract 8:85-89, 1990
5. Bras A, Aguas AP: Diabetes-prone NOD mice are resistant to Mycobacterium avium and the infection prevents autoimmune disease. Immunology 89:20-25, 1996
6. Oldstone MB: Viruses as therapeutic agents. I. Treatment of nonobese insulin-dependent diabetes mice with virus prevents insulin-dependent diabetes mellitus while maintaining general immune competence. J Exp Med 171:2077-2089, 1990
7. Takei I, Asaba Y, Kasatani T, Maruyama T, Watanabe K, Yanagawa T, Saruta T, Ishii T: Suppression of development of diabetes in NOD mice by lactate dehydrogenase virus infection. J Autoimmun 5:665-673, 1992
8. Wilberz S, Partke HJ, Dagnaes-Hansen F, Herberg L: Persistent MHV (mouse hepatitis virus) infection reduces the incidence of diabetes mellitus in non-obese diabetic mice. Diabetologia 34:2-5, 1991
9. Cooke A, Tonks P, Jones FM, O'Shea H, Hutchings P, Fulford AJ, Dunne DW: Infection with Schistosoma mansoni prevents insulin dependent diabetes mellitus in non-obese diabetic mice. Parasite Immunol 21:169-176, 1999
10. Audibert F, Chedid L, Lefrancier P, Choay J, Lederer E: Relationship between chemical structure and adjuvant activity of some synthetic analogues of N-acetyl-muramyl-L-alanyl-D-isoglutamine (MDP). Ann Immunol (Paris) 128C:653-661, 1977
11. Chedid L, Parant M, Parant F, Audibert F, Lefrancier F, Choay J, Sela M: Enhancement of certain biological activities of muramyl dipeptide derivatives after conjugation to a multi-poly(DL-alanine)-poly(L-lysine) carrier. Proc Natl Acad Sci U S A 76:6557-6561, 1979
12. Chang YH, Pearson CM, Chedid L: Adjuvant polyarthritis. V. Induction by N-acetylmuramyl-L-alanyl-D-isoglutamine, the smallest peptide subunit of bacterial peptidoglycan. J Exp Med 153:1021-1026, 1981
13. Shehadeh N, Calcinaro F, Bradley BJ, Bruchlim I, Vardi P, Lafferty KJ: Effect of adjuvant therapy on development of diabetes in mouse and man. Lancet 343:706-707, 1994
14. Lucas C, Bald LN, Fendly BM, Mora-Worms M, Figari IS, Patzer EJ, Palladino MA: The autocrine production of transforming growth factor-beta 1 during lymphocyte activation: a study with a monoclonal antibody-based ELISA. J Immunol 145:1415-1422, 1990
15. Castro AG, Neighbors M, Hurst SD, Zonin F, Silva RA, Murphy E, Liu YJ, O'Garra A: Anti-interleukin 10 receptor monoclonal antibody is an adjuvant for T helper cell type 1 responses to soluble antigen only in the presence of lipopolysaccharide. J Exp Med 192:1529-1534, 2000
16. Bahr GM, Carelli C, Audibert F, Modabber F, Chedid L: Analysis of the antigenic relationship of various derivatives of n-acetyl-muramyl-l-ala- disoglutamine (MDP), using anti-MDP antibodies. Mol Immunol 19:737-745, 1982
17. Specter S, Cimprich R, Friedman H, Chedid L: Stimulation of an enhanced in vitro immune response by a synthetic adjuvant, muramyl dipeptide. J Immunol 120:487-491, 1978
18. Parant MA, Pouillart P, Le Contel C, Parant FJ, Chedid LA, Bahr GM: Selective modulation of lipopolysaccharide-induced death and cytokine production by various muramyl peptides. Infect Immun 63:110-115, 1995
19. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR: CD1 recognition by mouse NK1+ T lymphocytes. Science 268:863-865, 1995
20. Bloemendal A, Van der Zee R, Rutten VP, van Kooten PJ, Farine JC, van Eden W: Experimental immunization with anti-rheumatic bacterial extract OM-89 induces T cell responses to heat shock protein (hsp)60 and hsp70; modulation of peripheral immunological tolerance as its possible mode of action in the treatment of rheumatoid arthritis (RA). Clin Exp Immunol 110:72-78, 1997
21. Vischer TL: Subreum (OM-8980): an anti-arthritic E. coli extract. Clin Exp Rheumatol 11 (Suppl. 8):S121-S123, 1993
22. Dhaher YY, Khamashta MA, Hartley B, Taub N, Farine JC, Hughes GR: The effect of OM-89 (Subreum) on the murine model of systemic lupus erythematosus MRL-lpr/lpr. Lupus 6:436-440, 1997
23. Keyser FD, Mielants H, Veys EM: Current use of biologicals for the treatment of spondyloarthropathies. Expert Opin Pharmacother 2:85-93, 2001
24. Kolb H, Worz-Pagenstert U, Kleemann R, Rothe H, Rowsell P, Scott FW: Cytokine gene expression in the BB rat pancreas: natural course and impact of bacterial vaccines. Diabetologia 39:1448-1454, 1996
25. Hartmann B, Bellmann K, Ghiea I, Kleemann R, Kolb H: Oral insulin for diabetes prevention in NOD mice: potentiation by enhancing Th2 cytokine expression in the gut through bacterial adjuvant. Diabetologia 40:902-909, 1997
26. Schaad UB, Mutterlein R, Goffin H: Immunostimulation with OM-85 in children with recurrent infections of the upper respiratory tract: a double-blind, placebo-controlled multicenter study. Chest 122:2042-2049, 2002
27. Del-Rio-Navarro BE, Luis Sienra-Monge JJ, Berber A, Torres-Alcantara S, Avila-Castanon L, Gomez-Barreto D: Use of OM-85 BV in children suffering from recurrent respiratory tract infections and subnormal IgG subclass levels. Allergol Immunopathol (Madr) 31:7-13, 2003
28. Bowman LM, Holt PG: Selective enhancement of systemic Th1 immunity in immunologically immature rats with an orally administered bacterial extract. Infect Immun 69:3719-3727, 2001
29. Kitani A, Fuss I, Nakamura K, Kumaki F, Usui T, Strober W: Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J Exp Med 198:1179-1188, 2003
30. Nakamura K, Kitani A, Strober W: Cell contact-dependent immunosuppression by CD4(+)CD25(+) regulatory T cells is mediated by cell surface-bound transforming growth factor beta. J Exp Med 194:629-644, 2001
31. Nakamura K, Kitani A, Fuss I, Pedersen A, Harada N, Nawata H, Strober W: TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol 172:834-842, 2004
32. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L: TGF-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9:1202-1208, 2003
33. Bach JF, Francois Bach J: Regulatory T cells under scrutiny. Nat Rev Immunol 3:189-198, 2003
34. Araujo LM, Lefort J, Nahori MA, Diem S, Zhu R, Dy M, Leite-de-Moraes MC, Bach JF, Vargaftig BB, Herbelin A: Exacerbated Th2-mediated airway inflammation and hyperresponsiveness in autoimmune diabetes-prone NOD mice: a critical role for CD1d-dependent NKT cells. Eur J Immunol 34:327-335, 2004
35. Sharif S, Arreaza GA, Zucker P, Mi QS, Sondhi J, Naidenko OV, Kronenberg M, Koezuka Y, Delovitch TL, Gombert JM, Leite-De-Moraes M, Gouarin C, Zhu R, Hameg A, Nakayama T, Taniguchi M, Lepault F, Lehuen A, Bach JF, Herbelin A: Activation of natural killer T cells by alpha-galactosylceramide treatment prevents the onset and recurrence of autoimmune type 1 diabetes. Nat Med 7:1057-1062, 2001
36. Lehuen A, Lantz O, Beaudoin L, Laloux V, Carnaud C, Bendelac A, Bach JF, Monteiro RC: Overexpression of natural killer T cells protects Valpha14-Jalpha281 transgenic nonobese diabetic mice against diabetes. J Exp Med 188:1831-1839, 1998
37. Shi FD, Flodstrom M, Balasa B, Kim SH, Van Gunst K, Strominger JL, Wilson SB, Sarvetnick N: Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse. Proc Natl Acad Sci U S A 98:6777-6782, 2001
38. Van Kaer L: Natural killer T cells as targets for immunotherapy of autoimmune diseases. Immunol Cell Biol 82:315-322, 2004
39. Oki S, Chiba A, Yamamura T, Miyake S: The clinical implication and molecular mechanism of preferential IL-4 production by modified glycolipid-stimulated NKT cells. J Clin Invest 113:1631-1640, 2004
40. Mi QS, Ly D, Zucker P, McGarry M, Delovitch TL: Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T-cells. Diabetes 53:1303-1310, 2004
41. Mi QS, Meagher C, Delovitch TL: CD1d-restricted NKT regulatory cells: functional genomic analyses provide new insights into the mechanisms of protection against type 1 diabetes. Novartis Found Symp 252:146-160 [discussion 160-144, 203-110], 2003
42. Qin HY, Chaturvedi P, Singh B: In vivo apoptosis of diabetogenic T cells in NOD mice by IFN-gamma/TNF-alpha. Int Immunol 16:1723-1732, 2004
43. Christen U, Benke D, Wolfe T, Rodrigo E, Rhode A, Hughes AC, Oldstone MB, von Herrath MG: Cure of prediabetic mice by viral infections involves lymphocyte recruitment along an IP-10 gradient. J Clin Invest 113:74-84, 2004
44. Fu S, Zhang N, Yopp AC, Chen D, Mao M, Zhang H, Ding Y, Bromberg JS: TGF-beta induces Foxp3 + T-regulatory cells from CD4 + CD25 - precursors. Am J Transplant 4:1614-1627, 2004